GlaxoSmithKline Q2 beats despite Advair hit, lower margins
July 29, 2015 at 07:10 AM EDT
LONDON, July 29 (Reuters) - A further slide in sales of lung drug Advair and lower profit margins following a business overhaul hit GlaxoSmithKline in the second quarter, although core earnings per share fell by a less-than-expected 9 percent.
